Hans Schreiber to Humans
This is a "connection" page, showing publications Hans Schreiber has written about Humans.
Connection Strength
0.336
-
CD4+ T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy. Sci Immunol. 2024 09 13; 9(99):eadp6529.
Score: 0.028
-
Criteria to make animal studies more relevant to treating human cancer. Curr Opin Immunol. 2022 02; 74:25-31.
Score: 0.023
-
Fibroblasts: Dangerous travel companions. J Exp Med. 2019 03 04; 216(3):479-481.
Score: 0.019
-
Editorial overview: tumour immunology. Curr Opin Immunol. 2015 Apr; 33:ix-xi.
Score: 0.015
-
Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol. 2015 Apr; 33:112-9.
Score: 0.015
-
Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell. 2013 Apr 15; 23(4):516-26.
Score: 0.013
-
Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res. 2012 May 01; 18(9):2526-33.
Score: 0.012
-
Targeting stroma to treat cancers. Semin Cancer Biol. 2012 Feb; 22(1):41-9.
Score: 0.012
-
Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes. Cancer Immun. 2011 Jun 30; 11:2.
Score: 0.011
-
Tumor-specific immune responses. Semin Immunol. 2008 Oct; 20(5):265-6.
Score: 0.009
-
Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest. 2008 Nov; 118(11):3574-81.
Score: 0.009
-
Specificity in cancer immunotherapy. Semin Immunol. 2008 Oct; 20(5):276-85.
Score: 0.009
-
Cancer. Quo vadis, specificity? Science. 2008 Jan 11; 319(5860):164-5.
Score: 0.009
-
The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol. 2006 Apr; 18(2):226-31.
Score: 0.008
-
Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases. Oncoimmunology. 2025 Dec; 14(1):2514041.
Score: 0.007
-
Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire. J Immunother Cancer. 2025 May 02; 13(5).
Score: 0.007
-
Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004 Dec; 14(6):433-9.
Score: 0.007
-
One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication. Clin Cancer Res. 2024 Apr 15; 30(8):1642-1654.
Score: 0.007
-
Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-gamma pathway but not IL-12 or IL-18. J Immunol. 2004 Mar 01; 172(5):3243-51.
Score: 0.007
-
The safety and efficacy of systemic delivery of a new liver-de-targeted TGFß signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model. Cancer Gene Ther. 2024 Apr; 31(4):574-585.
Score: 0.007
-
Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr Opin Immunol. 2003 Dec; 15(6):725-30.
Score: 0.007
-
Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model. J Immunother Cancer. 2023 05; 11(5).
Score: 0.006
-
Immunodominance and tumor escape. Semin Cancer Biol. 2002 Feb; 12(1):25-31.
Score: 0.006
-
Immunological enhancement of primary tumor development and its prevention. Semin Cancer Biol. 2000 Oct; 10(5):351-7.
Score: 0.005
-
Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides. Proc Natl Acad Sci U S A. 2020 06 30; 117(26):15148-15159.
Score: 0.005
-
LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor ß Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models. Hum Gene Ther. 2020 08; 31(15-16):863-880.
Score: 0.005
-
Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. JCI Insight. 2019 11 01; 4(21).
Score: 0.005
-
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. Clin Cancer Res. 2020 02 01; 26(3):679-689.
Score: 0.005
-
A strategy for generating cancer-specific monoclonal antibodies to aberrant O-glycoproteins: identification of a novel dysadherin-Tn antibody. Glycobiology. 2019 04 01; 29(4):307-319.
Score: 0.005
-
Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplant. 2018 11; 53(11):1379-1389.
Score: 0.005
-
Unique tumor antigens redefined as mutant tumor-specific antigens. Semin Immunol. 1996 Oct; 8(5):289-93.
Score: 0.004
-
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity. 2016 06 21; 44(6):1444-54.
Score: 0.004
-
Prevention of runting and cachexia by a chimeric TNF receptor-Fc protein. Clin Immunol Immunopathol. 1993 Nov; 69(2):215-22.
Score: 0.003
-
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013 Oct; 14(10):1014-22.
Score: 0.003
-
Footprinting of individual tumors and their variants by constitutive cytokine expression patterns. Cancer Res. 1993 May 01; 53(9):1978-81.
Score: 0.003
-
IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8158-63.
Score: 0.003
-
Design and characterization of a protein superagonist of IL-15 fused with IL-15Ra and a high-affinity T cell receptor. Biotechnol Prog. 2012 Nov-Dec; 28(6):1588-97.
Score: 0.003
-
Tumor antigens. Annu Rev Immunol. 1992; 10:617-44.
Score: 0.003
-
Antibody recognition of a unique tumor-specific glycopeptide antigen. Proc Natl Acad Sci U S A. 2010 Jun 01; 107(22):10056-61.
Score: 0.003
-
Tumor-specific antigens and tumor-specific mutant proteins in mouse and man. Haematol Blood Transfus. 1989; 32:284-8.
Score: 0.002
-
Unique tumor-specific antigens. Annu Rev Immunol. 1988; 6:465-83.
Score: 0.002
-
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007 Aug 01; 179(3):1960-8.
Score: 0.002
-
Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol Oncol Clin North Am. 2006 Jun; 20(3):567-84.
Score: 0.002
-
Active immunization against cancer cells: impediments and advances. Semin Oncol. 1998 Dec; 25(6):697-706.
Score: 0.001
-
Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Ann Surg. 1998 Mar; 227(3):372-9.
Score: 0.001
-
[Immunocytologic detection of disseminated tumor cells in the peritoneal cavity and bone marrow in patients with pancreatic carcinoma]. Chirurg. 1994 Dec; 65(12):1111-5.
Score: 0.001
-
Immunocytological detection of micrometastatic cells: comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int J Cancer. 1994 May 01; 57(3):330-5.
Score: 0.001
-
Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol. 1994 Apr; 12(4):725-9.
Score: 0.001
-
Antiproliferative effects exerted by recombinant human tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) on human pancreatic tumor cell lines. Pancreas. 1988; 3(2):180-8.
Score: 0.001
-
[Clinical aspects and therapy of Merkel cell tumor--report of 4 personal cases and review of the literature]. Langenbecks Arch Chir. 1988; 373(3):173-81.
Score: 0.001
-
[CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon]. Dtsch Med Wochenschr. 1984 Dec 21; 109(51-52):1949-54.
Score: 0.000